Trial Profile

A Phase I study to evaluate PBI-0451

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 07 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pomotrelvir (Primary)
Indications COVID 2019 infections
Focus Adverse reactions
Sponsors Pardes Biosciences

Most Recent Events

07 Feb 2022 New trial record
03 Feb 2022 According to Pardes Biosciences media release, the United States Food and Drug Administration (FDA) has cleared Investigational New Drug (IND) application for PBI-0451 for the treatment and prevention of SARS-CoV-2 infections and associated diseases.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com